Questions about Amgen, Inc.’s KRAS G12C inhibitor sotorasib – newly branded Lumakras – are never in short supply, but the company’s updates regarding the oral cancer drug as part of its first quarter earnings reporting on 27 April raised more questions than it answered.
The biggest question of all is why Amgen has initiated a Phase II study testing a 240mg once-daily dose versus...